This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Liver Transplant Recipients.

This study has been completed.
Astellas Pharma Taiwan, Inc.
Information provided by:
Astellas Pharma Inc Identifier:
First received: July 18, 2008
Last updated: September 14, 2009
Last verified: September 2009
The purpose of this study is to compare the efficacy and safety of Prograf extended release(XL) plus MMF with Prograf plus MMF and steroid withdrawal in de novo Liver transplant recipients

Condition Intervention Phase
Liver Transplantation Transplantation Immunology Host vs Graft Reaction Drug: Prograf-XL Drug: Prograf Drug: MMF Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (Tacrolimus)/MMF and Extended Release (XL) Tacrolimus /MMF and Steroid Withdraw in de Novo Liver Transplant Recipients.

Resource links provided by NLM:

Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • Incidence of biopsy confirmed acute rejection (local assessment of biopsies performed due to hepatic dysfunction) during the 6 months post-transplant. [ Time Frame: 6 month ]

Secondary Outcome Measures:
  • Patient and graft survival rates during the 6 and 12 months post-transplant [ Time Frame: 6 and 12 month ]
  • Incidence of biopsy confirmed acute rejection (local assessment of biopsies performed due to hepatic dysfunction) during the 12 months post-transplant [ Time Frame: 12 month ]
  • Incidence of anti-lymphocyte antibody therapy for treatment of rejection during the 6 and 12 months post-transplant [ Time Frame: 6 and 12 month ]

Enrollment: 48
Study Start Date: December 2007
Study Completion Date: September 2009
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Prograf-XL + MMF Drug: Prograf-XL
Other Names:
  • tacrolimus extended release
  • FK506E
  • MR4
Drug: MMF
Other Name: Mycophenolate Mofetil
Active Comparator: Prograf + MMF Drug: Prograf
Other Names:
  • tacrolimus
  • FK506
Drug: MMF
Other Name: Mycophenolate Mofetil


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient has been fully informed and has signed an IRB approved informed consent form and is willing and able to follow study procedures
  • Patient is a primary liver transplant recipient
  • Patient must receive first dose of XL or Prograf (or IV tacrolimus for subjects unable to tolerate oral study drug) within 48 hours of transplantation
  • Female patients of child bearing potential must have a negative urine or serum pregnancy test within 7 days prior to transplant

Exclusion Criteria:

  • Patient has previously received or is receiving an organ transplant other than a liver
  • Recipient or donor is known to be seropositive for human immunodeficiency virus (HIV)
  • Patient has received a liver transplant from a non-heart beating donor
  • Patient has received an ABO incompatible donor liver
  • Patient has a current malignancy or a history of malignancy (within the past 5 years), except hepatocellular carcinoma within UCSF Criteria 21 and basal or non-metastatic squamous cell carcinoma of skin that has been treated successfully
  • Patient has fulminant hepatic failure, unless hemodynamically stable
  • Patient has an uncontrolled concomitant infection, a systemic infection requiring treatment (except viral hepatitis), or any other unstable medical condition that could interfere with the study objectives
  • Patient has severe diarrhea, vomiting, active peptic ulcer or gastrointestinal disorder that may affect the absorption of tacrolimus
  • Patient is currently taking or has been taking an investigational drug in the 30 days prior to transplant
  • Patient has a known hypersensitivity to tacrolimus, mycophenolate mofetil or corticosteroids
  • Patient is pregnant or lactating
  • Patient is unlikely to comply with the visits scheduled in the protocol, including the protocol biopsies
  • Patient has any form of substance abuse, psychiatric disorder or a condition that, in the opinion of the investigator, may invalidate communication with the investigator
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00720408

Kaohsiung, Taiwan, 833
Taipei, Taiwan, 100
Taipei, Taiwan, 112
Taoyuan, Taiwan, 333
Sponsors and Collaborators
Astellas Pharma Inc
Astellas Pharma Taiwan, Inc.
Study Chair: Central Contact Astellas Pharma Inc
  More Information

Responsible Party: Director, Astellas Pharma Inc. Identifier: NCT00720408     History of Changes
Other Study ID Numbers: PRGXLLTx-0702-TW
Study First Received: July 18, 2008
Last Updated: September 14, 2009

Keywords provided by Astellas Pharma Inc:
Graft loss
Combination drug therapy
Randomized controlled trial
Open level method

Additional relevant MeSH terms:
Mycophenolate mofetil
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 19, 2017